期刊文献+

紫杉醇脂质体治疗不同肿瘤分期宫颈癌患者的近期疗效分析

Short Term Efficacy of Paclitaxel Liposome in the Treatment of Cervical Cancer Patients with Different Tumor Stages
下载PDF
导出
摘要 目的分析紫杉醇酯质体在不同肿瘤分期宫颈癌患者中的治疗效果。方法从该院2014年1月—2016年2月收治的宫颈癌患者中随机抽选51例,根据肿瘤分期将其分为:I期(17)组、IIA期(17)组、IIB期(17)组,行顺铂基础上加用紫杉醇酯质体方案化疗,评定不同分期患者的治疗效果。观察两组治疗前后肿瘤大小变化、不良反应并进行疗效判定。结果 IIB期患者的疾病缓解率为88.2%,明显高于I期、IIA期缓解率的70.6%、76.5%,差异无统计学意义,P<0.05;I期、IIA期、IIB期患者治疗期间均出现不良反应,发生率分别为29.4%、17.6%、11.8%,差异无统计学意义,P>0.05。结论临床宫颈癌患者中实施紫杉醇酯质体化疗效果显著,且随着肿瘤分期升高,化疗效果更为明显,可为随后的手术方案实施提供参考依据。 Objective To analyze the effect of paclitaxel liposome in cervical cancer patients with different tumor stages.Methods From cervical cancer patients in our hospital from January 2014 to February 2016 were randomly selected in 51 cases, according to the tumor stage divided: phase I(17) group, group IIA(17), IIb(17) group, cisplatin based on the use of paclitaxel liposome chemotherapy, evaluation of different staging in patients with therapeutic effect. Results Patients with stage IIB disease remission rate was 88.2%, significantly higher than the phase I, IIA remission rate of 70.6%, 76.5%, three groups of statistical difference,(P〈0.05). Phase I, IIA, IIb patients during adverse reactions occurred, incidence rate of29.4%, 17.6%, 11.8%, respectively. There is no difference in statistics(P〉0.05).Conclusion In patients with cervical cancer, paclitaxel liposome chemotherapy has a significant effect, and with the increase of tumor stage, chemotherapy effect is more obvious, which can provide reference for the subsequent implementation of the program.
出处 《中外医疗》 2016年第26期142-143,147,共3页 China & Foreign Medical Treatment
关键词 紫杉醇酯质体 宫颈癌 肿瘤分期 化疗效果 Paclitaxel Liposome Cervical Cancer Tumor Stage Chemotherapy Effect
  • 引文网络
  • 相关文献

参考文献8

二级参考文献90

  • 1郑亚峰.紫杉醇脂质体联合卡铂与传统紫杉醇联合卡铂治疗晚期卵巢癌的疗效及毒副作用比较[J].柳州医学,2010(3):63-65. 被引量:12
  • 2贾颖,瞿全新.宫颈癌同步放化疗临床应用进展[J].国外医学(妇产科学分册),2006,33(2):120-123. 被引量:16
  • 3张书旭,王兆武,沈国辉,林生趣.宫颈癌三维适形调强放疗剂量分布特性研究[J].现代肿瘤医学,2006,14(7):882-884. 被引量:8
  • 4Tharavichitkul E, Klunkin P, Lorvidhaya V,et al. The effects of two HDR brachytherapy schedules in locally advanced cervi- cal cancer treated with concurrent chemoradiation: a study from Chiang Mai, Thailand [ J ]. J Radiat Res, 2012, 53 (2) :281.
  • 5Nagai Y, Toita T, Wakayama A, et al. Concurrent chemora- diotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix [J] . Anticancer Res, 2012, 32 (4) : 1475.
  • 6Nogueira A, Catarino R, Faustino I, et al. Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy [ J ] . Gene, 2012, 504 (2): 279.
  • 7Klimek M, Kruczak A, Rys J, et al. Clinico -morphological parameters affecting survival of patients with advanced cervical cancer [J]. Pol J Pathol, 2011,62 (4) : 250.
  • 8Sato S, Fujiwara HI Oishi T, et al. Evaluation of a formula for individual dosage of nedaplatin based on renal function [J] . Cancer Chemother Pharmacol, 2012, 69 (3) : 599.
  • 9Vercellino GF, Piek JM, Schneider A, et al. Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer[J] . Gynecol Oncol, 2012, 126 (3) : 325.
  • 10WANG N, GUAN Q L, WANG K, et al. Radiochemotherapy ver- sus radiotherapy in locally advanced cervical cancer: a meta- analysis[J]. Arch Gynecol Obstet, 2011, 283( 1 ) : 103 - 108.

共引文献189

;
使用帮助 返回顶部